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SUMMARY
The aim of this study was to systematically consider the evidence for polymyalgia rheumatica (PMR) as a 
paraneoplastic disease.
A systematic review of Medline and Embase was conducted from their inception to February 2017. Risk of bias 
was assessed using the Newcastle-Ottawa tool. Data were extracted regarding the PMR-cancer association, the 
types of cancer associated with PMR and the presentation of PMR patients subsequently diagnosed with cancer. 
Twenty-three full text articles were reviewed from the 1174 unique references identified in the search. Nine 
articles were included in the final review. There was some evidence of an association between PMR and cancer 
in the short-term (first 6 to 12 months after diagnosis), but no evidence of an association after this time. Limited 
evidence suggests that lymphoma, prostate and haematological cancers may be those cancers more commonly 
diagnosed in those with PMR. There was little evidence to suggest what presenting features may be associated 
with the development of cancer. 
There is little evidence of PMR as a true paraneoplastic disease. However, there is reason to be cautious when 
making the diagnosis of PMR. Clinicians should be aware of this potential association both prior to making a 
diagnosis and throughout the course of the condition.
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n	 INTRODUCTION
Polymyalgia rheumatica (PMR) is a rela-tively common inflammatory rheumato-
logical disorder of older (>50 years) adults. 
Classical presenting symptoms include bi-
lateral hip and shoulder girdle pain and stiff-
ness, morning stiffness, raised inflammatory 
markers [classically elevated erythrocyte 
sedimentation rate (ESR) or C-reactive pro-
tein (CRP)] and systemic features such as 
pyrexia, fatigue and weight loss (1). In the 
absence of a gold standard diagnostic test, 
PMR remains a clinical diagnosis. Cur-
rent guidelines from the British Society for 
Rheumatology, and others, suggest that a 
variety of disorders should be excluded prior 
to making a diagnosis of PMR (2-4). These 
include other rheumatological conditions 
(including rheumatoid arthritis and fibro-
myalgia), endocrine diseases (e.g., hypothy-
roidism) and neurological conditions (e.g., 
Parkinson’s disease), drug-induced myalgia 
(e.g., from statin treatment), infection and 
active cancer. Definitively excluding ac-
tive cancer can be challenging and although 
simple screening investigations, such as a 
chest X-ray, are advocated by guidelines, 
more complex and invasive investigations 
are not indicated for all patients. 
The association between cancer and rheu-
matic disorders has long been recognised. 
Racanelli et al. (5) summarise these into 
three groups. First, patients where a rheu-
matic disorder is directly triggered by a 
tumour or its metastases (e.g. leukaemic 
synovitis); second, patients with an estab-
lished rheumatic condition who are at in-
creased risk of a specific malignancy [e.g., 
primary Sjögrens syndrome and lymphoma 
(6)]; and third, patients with paraneoplas-
tic diseases. This group arises where an 
apparently idiopathic rheumatic disease is 
actually the expression of an occult cancer 
that becomes clinically evident within a de-
fined timeframe [usually 2 years (7)]. Thus 
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a paraneoplastic syndrome is the term used 
to describe the clinical or systemic symp-
toms that are associated with a tumour but 
not caused by direct invasion of the target 
tissue. 
Paraneoplastic syndromes are thought to 
be caused by an altered immune response, 
either caused by antibody production (e.g., 
anti-Hu antibody syndrome and lung cancer, 
which presents as neuropathies) (8), aber-
rant hormone release [e.g., syndrome of in-
appropriate anti-diuretic hormone secretion, 
SIADH and lung cancer, leading to head-
ache, weakness and low sodium levels (9)] 
or abnormal cytokine release such as vascu-
lar endothelial growth factor (VEGF) (7).
Studies suggest that up to 8% of patients with 
cancer may have a paraneoplastic syndrome 
(9). Symptoms of a paraneoplastic syndrome 
can affect any organ system, including hae-
matological (e.g., haemolytic anaemia), cuta-
neous (e.g., scleroderma, clubbing), vascular 
(e.g., leucocytoclastic vasculitis, Raynaud’s 
phenomenon) and neurological systems (e.g., 
neuropathies or encephalomyelitis, stiff-man 
syndrome) (10). Common rheumatologi-
cal manifestations include hypertrophic os-
teoarthropathy, cancer associated myositis, 
paraneoplastic polyarthritis, and relapsing 
seronegative symmetric synovitis with pitting 
oedema (RS3PE) (6). 
However, for less specific symptoms, such 
as joint pain, establishing whether these are 
truly paraneoplastic is more controversial. 
Lortholary et al. (11) define a paraneoplastic 
syndrome using the following criteria:
1. presence of a cancer;
2. clinical presentation not directly due to 
the primary tumour or metastases;
3. absence of other non-neoplastic causes;
4. parallel evolution. 
A paraneoplastic syndrome is considered 
probable if three criteria were met and pos-
sible if one or two criteria were met.
For a condition such as PMR, which has no 
specific diagnostic test, establishing whether 
there is a true association between PMR and 
malignancy or whether it is a co-incidental 
existence of the two conditions is more dif-
ficult. Classically symptoms of a paraneo-
plastic syndrome regress after treatment of 
the underlying cancer. However, given the 
often rapid improvement of PMR symptoms 
with low dose glucocorticoids, proving such 
temporality is unethical and inappropriate. 
Given the controversy about whether this 
represents association or co-incidence, this 
review will consider the evidence for the as-
sociation between PMR and cancer. Specifi-
cally, it will consider timescales and wheth-
er any presenting features were associated 
with a later diagnosis of cancer to further 
elucidate the evidence surrounding the para-
neoplastic syndrome and PMR (12).
n	 MATERIALS AND METHODS
Search strategy
Our search strategy was based on that devel-
oped by Ungprasert et al. (13). The search 
was conducted in Medline (1946 February 
2017) and Embase (1974 February 2017). 
Full details can be found in the Appendix, 
but briefly the exploded MeSH term poly-
myalgia rheumatica was used in combina-
tion with text word searches for polymyalgia 
and PMR. This was combined with searches 
for the exploded MeSH term neoplasms and 
text word searches for neoplasm, cancer, 
malignancy, carcinoma, tumour and other 
appropriate terms. 
Inclusion and exclusion criteria
Inclusion criteria were:
1. cohort study (prospective or retrospec-
tive) or randomised controlled trial in-
cluding an exposed (PMR group) and an 
unexposed (non-PMR group), or a sys-
tematic review;
2. consider the association between a diag-
nosis of PMR and concomitant or subse-
quent diagnosis of cancer.
Exclusion criteria were:
1. case reports, case series or case-control 
study;
2. association between PMR and cancer/
paraneoplastic syndrome not considered; 
3. no full text article available (e.g., confer-
ence abstract), or no English language 
version of full paper available.
Study selection
Retrieved titles were screened against the 
inclusion and exclusion criteria by a single 
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reviewer (SM). The abstracts of the remain-
ing studies were then examined with studies 
not meeting the inclusion criteria excluded. 
Reasons for exclusion were recorded. Final-
ly, full texts of the remaining studies were 
reviewed and a final list of included studies 
was prepared (Figure 1).
Quality assessment
Assessment of study quality and the likeli-
hood of bias was conducted using the New-
castle-Ottawa scale (14). This scale uses a 
star rating so that each study receives a maxi-
mum score of four stars for sample selection 
(whether the sample is representative of the 
population of interest and how exposure is 
ascertained), two stars for comparability and 
three stars for outcome (how outcome was 
assessed and over what time period). For the 
purposes of this review, we discounted the 
comparability section, as it relates to control 
of potentially confounding factors, which 
we did not consider relevant to our question 
regarding an association between PMR and 
cancer, as we did not require this association 
to be causal. 
Data extraction
Data regarding the following were extracted 
from each study included in the review:
1. time frame between diagnosis of PMR 
and diagnosis of cancer;
2. types of cancer associated with PMR;
3. presentation of PMR that was later 
considered to be cancer, focussing par-
ticularly on clinical presenting features 
(e.g., failure to respond to glucocorticoid 
treatment);
4. the authors’ conclusions as to the nature 
of any PMR-cancer association.
n	 RESULTS
Results of the search
A total of 1174 unique citations were obtained 
(Figure 1). 1077 were excluded based on title 
screening and further 74 were excluded af-
ter abstract screening, leaving 23 full articles 
for review. After this final stage of screening, 
nine studies remained. The main reasons for 
exclusion of studies at the abstract and full 
text screening stages were that articles pre-
sented case reports or case series (n=40), that 
no original data or a systematic review were 
presented (n=20) or that a full paper was not 
available in English (n=13). 
Articles included in the review
Eight of the nine articles identified through 
the systematic search described cohort stud-
Figure 1 - Selection of articles for systematic review.
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ies (Table I) (15-22). Two articles utilised 
the same dataset, but with one considering 
the outcomes of cancer diagnosis and the 
other causes of death including cancer (19, 
20). Five of the articles (17-20, 22), all from 
Scandinavia, used an unexposed group taken 
from a database separate to the PMR group, 
but representative of the general population, 
whilst two studies [one from the UK (15), 
one from the USA (21)] selected an unex-
posed group from the same clinical source 
data as the exposed PMR group (Table I). A 
final study from Italy selected controls from 
the same hospital, but with a diagnosis of 
Table I - Description of studies included in the systematic review.
Muller et al. (15) Bellan et al. (16) Haga et al. (17) Ji et al. (18) Myklebust et al. (19) Myklebust et al. (20) Pfeiffer et al. (21) Schauffelberger et al. (22)
Study location UK Italy Norway Sweden Norway Norway USA Sweden
Year 2014 2017 1992 2010 2002 2003 2015 1995
Definition of PMR Aged ≥50 years. Read code for 
PMR in GPRD 1987-1999. ≥2 
oral corticosteroid prescriptions 
within 6 months of Read 
code. No pre-existing vascular 
disease or cancer at PMR 
diagnosis
Diagnosed with 
PMR in tertiary 
clinic. ≥2 years 
follow-up data
Diagnosed in hospital 1978-1983. 
PMR not differentiated from TA
Pain/stiffness in proximal muscles 
for ≥4 weeks; ESR≥40mm/h; No 
evidence of muscle disease, CTD  
or infection
Hospitalised with PMR/
GCA 1969-2006 (SHDR). 
PMR not distinguished  
from GCA
Diagnosed by rheumatologist/
in hospital with PMR or TA or 
hospitalised with another condition 
1987-1997.  
Fulfilled Bird or Hamrin criteria. 
Included those with cancer 
diagnosed around time of PMR 
diagnosis if PMR criteria fulfilled
Diagnosed by 
rheumatologist/in hospital 
with PMR or TA or 
hospitalised with another 
condition 1987-1997. 
Fulfilled Bird or Hamrin 
criteria
Rochester Epidemiology Project. PMR 
diagnosed by physician 1970-1999. 
≥50 years; bilateral aching and morning 
stiffness ≥30 minutes in ≥2 of: neck/
torso, shoulders/proximal arms, hips/
proximal thighs; ESR>40mm/h. Definite 
response to <20mg/d corticosteroids.  
Excluded if alternative diagnoses
Hospital patients 1985-1987 
screened negative for temporal artery 
abnormalities. Pain and stiffness in 
≥2 groups of proximal muscles for 
≥2 weeks. No inflammatory arthritis. 
ESR≥40mm/h. ≥50 years. No evidence 
of infection, malignancy, RA, SLE, 
periarteritis nodosa
Sample size of PMR 
group
2877 100 185: 91 PMR only, 54 TA only, 40 
PMR+TA
35,918 398 (315 PMR only) 315 359 220
Mean (SD) age of PMR 
sample (years)
72.0 (8.9) 73.2 (7.8) 69.6 (range 43-86) - - Female 72.4 (8.2); 
Male 71.2 (8.5)
73.5 (8.5) 72.9 (range 50-91)
% of PMR sample female 72.7 60 70.8 - 68.6 overall, (67.6 PMR only) 67.6 66.6 71
Follow-up time in PMR 
group (years)
Median 8.4 (IQR 3.9, 12.3) - - Median 8 (range 0-35) - Total follow-up time 1747 
years
Mean 11.8 (SD 6.7) Mean 36 months  
(range 0-52, median 36.8 months)
Definition of comparator 
group
Matched (year of birth, gender, 
general practice) from GPRD. 
No pre-existing vascular 
disease or cancer at matched 
PMR patient’s diagnosis
Diagnosed with 
osteoarthritis in 
tertiary clinic ≥2 
years follow-up 
data
Matched (year of birth, sex) from 
Central Population Registry to 
PMR group. Alive at time of PMR 
diagnosis and living in same county
No defined group Matched (month and year of birth) 
from Central Population Registry. 
Alive at time PMR diagnosis
Matched (month and 
year of birth) from Central 
Population Registry. Alive 
at time PMR diagnosis
Matched (year of birth, sex, 
length medical history) from Rochester 
Epidemiology Project
Matched normal population  
of the same age
Sample size of 
comparator group
9422 (4:1 matched) 702 5:1 matched to PMR group N/A 1592 (4:1 matched) 1260 (4:1 matched) 357 Unclear
Mean (SD) age of 
comparator sample
71.5 (9.1) 61.3 (12.8) - N/A - - 73.3 (8.5) -
% of comparator sample 
female
72.8 82.5 - N/A 68.6 - 66.9 -
Follow-up time in 
comparator group
Median 7.6 (IQR 3.3, 12.3) - - N/A NS Tempo di follow-up  
totale di 6656 anni
Media 10,7 (SD 7,4) Unclear
Ascertainment of cancer 
outcome
Read code for “neoplasm” 
(chapter B, excluding B7 codes 
(non-malignant neoplasms)  
in GPRD
Record review Cancer Registry of Norway until  
end 1987, regardless of date  
of PMR/TA diagnosis. Some cancers 
are before PMR/TA diagnosis
Swedish Cancer Registry 
up to 2006. Expected 
number of cancers 
calculated based on 
national population size
Cancer Registry of Norway  
until end 1998. All cases  
of cancer included.  
Type, time and site of cancer 
recorded
Date and cause of death 
from Statistics Norway. 
Cancer could be among 
causes of death
Record review cross-referenced with 
Mayo Clinic Cancer Registry. Date, type 
and site of malignancy recorded
Derived from medical  
and death records.  
Only fatal cancers considered
Quality assessment 
(Newcastle-Ottawa scale)
Selection 4 2 4 2 4 4 3 3
Outcome 3 3 2 3 3 3 3 3
TA, temporal arteritis; GCA, giant cell arteritis; SHDR, Swedish Hospital Discharge Register;  RA, rheumatoid arthritis; SLE, systematic lupus erythematosus;  
GPRD, General Practice Research Database; ESR, erythrocyte sedimentation rate; CTD, connective tissue disease; IQR, inter-quartile range; SD, standard deviation; N/A, not applicable.
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osteoarthritis (16). All studies used a clini-
cal diagnosis of PMR, ascertained from the 
medical records, whilst six of the studies also 
used specified criteria for inclusion (15, 17, 
19-22). Four of the articles explicitly stated 
that they did not differentiate PMR from gi-
ant cell arteritis (GCA) (17-20), one study in-
cluded only those patients with PMR symp-
toms and a negative temporal artery biopsy 
(22). In the remaining three studies, it was not 
clear whether those with concomitant GCA 
were excluded, but all patients were required 
to have PMR (15, 16, 21). All cancer diagno-
ses were obtained by medical record review 
Table I - Description of studies included in the systematic review.
Muller et al. (15) Bellan et al. (16) Haga et al. (17) Ji et al. (18) Myklebust et al. (19) Myklebust et al. (20) Pfeiffer et al. (21) Schauffelberger et al. (22)
Study location UK Italy Norway Sweden Norway Norway USA Sweden
Year 2014 2017 1992 2010 2002 2003 2015 1995
Definition of PMR Aged ≥50 years. Read code for 
PMR in GPRD 1987-1999. ≥2 
oral corticosteroid prescriptions 
within 6 months of Read 
code. No pre-existing vascular 
disease or cancer at PMR 
diagnosis
Diagnosed with 
PMR in tertiary 
clinic. ≥2 years 
follow-up data
Diagnosed in hospital 1978-1983. 
PMR not differentiated from TA
Pain/stiffness in proximal muscles 
for ≥4 weeks; ESR≥40mm/h; No 
evidence of muscle disease, CTD  
or infection
Hospitalised with PMR/
GCA 1969-2006 (SHDR). 
PMR not distinguished  
from GCA
Diagnosed by rheumatologist/
in hospital with PMR or TA or 
hospitalised with another condition 
1987-1997.  
Fulfilled Bird or Hamrin criteria. 
Included those with cancer 
diagnosed around time of PMR 
diagnosis if PMR criteria fulfilled
Diagnosed by 
rheumatologist/in hospital 
with PMR or TA or 
hospitalised with another 
condition 1987-1997. 
Fulfilled Bird or Hamrin 
criteria
Rochester Epidemiology Project. PMR 
diagnosed by physician 1970-1999. 
≥50 years; bilateral aching and morning 
stiffness ≥30 minutes in ≥2 of: neck/
torso, shoulders/proximal arms, hips/
proximal thighs; ESR>40mm/h. Definite 
response to <20mg/d corticosteroids.  
Excluded if alternative diagnoses
Hospital patients 1985-1987 
screened negative for temporal artery 
abnormalities. Pain and stiffness in 
≥2 groups of proximal muscles for 
≥2 weeks. No inflammatory arthritis. 
ESR≥40mm/h. ≥50 years. No evidence 
of infection, malignancy, RA, SLE, 
periarteritis nodosa
Sample size of PMR 
group
2877 100 185: 91 PMR only, 54 TA only, 40 
PMR+TA
35,918 398 (315 PMR only) 315 359 220
Mean (SD) age of PMR 
sample (years)
72.0 (8.9) 73.2 (7.8) 69.6 (range 43-86) - - Female 72.4 (8.2); 
Male 71.2 (8.5)
73.5 (8.5) 72.9 (range 50-91)
% of PMR sample female 72.7 60 70.8 - 68.6 overall, (67.6 PMR only) 67.6 66.6 71
Follow-up time in PMR 
group (years)
Median 8.4 (IQR 3.9, 12.3) - - Median 8 (range 0-35) - Total follow-up time 1747 
years
Mean 11.8 (SD 6.7) Mean 36 months  
(range 0-52, median 36.8 months)
Definition of comparator 
group
Matched (year of birth, gender, 
general practice) from GPRD. 
No pre-existing vascular 
disease or cancer at matched 
PMR patient’s diagnosis
Diagnosed with 
osteoarthritis in 
tertiary clinic ≥2 
years follow-up 
data
Matched (year of birth, sex) from 
Central Population Registry to 
PMR group. Alive at time of PMR 
diagnosis and living in same county
No defined group Matched (month and year of birth) 
from Central Population Registry. 
Alive at time PMR diagnosis
Matched (month and 
year of birth) from Central 
Population Registry. Alive 
at time PMR diagnosis
Matched (year of birth, sex, 
length medical history) from Rochester 
Epidemiology Project
Matched normal population  
of the same age
Sample size of 
comparator group
9422 (4:1 matched) 702 5:1 matched to PMR group N/A 1592 (4:1 matched) 1260 (4:1 matched) 357 Unclear
Mean (SD) age of 
comparator sample
71.5 (9.1) 61.3 (12.8) - N/A - - 73.3 (8.5) -
% of comparator sample 
female
72.8 82.5 - N/A 68.6 - 66.9 -
Follow-up time in 
comparator group
Median 7.6 (IQR 3.3, 12.3) - - N/A NS Tempo di follow-up  
totale di 6656 anni
Media 10,7 (SD 7,4) Unclear
Ascertainment of cancer 
outcome
Read code for “neoplasm” 
(chapter B, excluding B7 codes 
(non-malignant neoplasms)  
in GPRD
Record review Cancer Registry of Norway until  
end 1987, regardless of date  
of PMR/TA diagnosis. Some cancers 
are before PMR/TA diagnosis
Swedish Cancer Registry 
up to 2006. Expected 
number of cancers 
calculated based on 
national population size
Cancer Registry of Norway  
until end 1998. All cases  
of cancer included.  
Type, time and site of cancer 
recorded
Date and cause of death 
from Statistics Norway. 
Cancer could be among 
causes of death
Record review cross-referenced with 
Mayo Clinic Cancer Registry. Date, type 
and site of malignancy recorded
Derived from medical  
and death records.  
Only fatal cancers considered
Quality assessment 
(Newcastle-Ottawa scale)
Selection 4 2 4 2 4 4 3 3
Outcome 3 3 2 3 3 3 3 3
TA, temporal arteritis; GCA, giant cell arteritis; SHDR, Swedish Hospital Discharge Register;  RA, rheumatoid arthritis; SLE, systematic lupus erythematosus;  
GPRD, General Practice Research Database; ESR, erythrocyte sedimentation rate; CTD, connective tissue disease; IQR, inter-quartile range; SD, standard deviation; N/A, not applicable.
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(either clinical records or cancer registration 
databases). All studies except Ji et al. (18) 
gained three or four stars for cohort selection 
when assessed using the Newcastle-Ottawa 
criteria and all except Haga et al. (17) gained 
the full three stars for outcome ascertainment.
What is the evidence of an association 
between PMR and cancer?
The methods of comparing and reporting 
the association between PMR and cancer 
varied greatly, as did the findings. Five of 
the studies found there to be no difference 
in the rates of cancer diagnoses in those 
with and without PMR (17, 19-22). Two 
reported an increase in cancer diagnoses in 
PMR patients compared to those without 
PMR. Bellan et al. (16) reported an odds 
ratio of 5.1 (95% CI 2.9, 8.9) for their ter-
tiary care PMR group to be diagnosed with 
cancer compared to the comparator group 
and Ji et al. (18) showed a standardised inci-
dence ratio of 1.19 (1.15, 1.23) in their hos-
pital population with PMR compared to the 
general population (Table II). Muller et al. 
(15) reported that whilst the risk of a cancer 
diagnosis decreased over time, there was a 
significant increase in the risk of cancer in 
the first six months after a PMR diagnosis 
[hazard ratio 1.69 (1.18, 2.42)], but the risk 
was then attenuated [1.03 (0.70, 1.51) at 6 to 
12 months after PMR diagnosis]. A higher 
risk closer to the time of initial PMR diag-
nosis was also noted by Ji et al. (18).
The final study identified was a systematic 
review and meta-analysis of malignancy in 
Table II - Association of PMR with cancer.
Muller  
et al. (15)
Bellan  
et al. (16)
Haga  
et al. (17)
Ji  
et al. (18)
Myklebust  
et al. (19)
Myklebust 
et al. (20)
Pfeiffer  
et al. (21)
Schauffelberger 
et al. (22)
Incidence 
of cancer 
outcome in 
PMR group
23.2%  
(no 
timescale 
given)
24%  
(no timescale 
given)
Unclear 3941 cases 8.6% 
(males 13.4%, 
females 7.5%)
3.2% (no 
timescale 
given)
10 year 
cumulative 
incidence (SD)
Any: 13.8 (2.0)
Solid: 13.1 (1.9)
Haematologic:
1.2 (0.6)
Observed 
number of 
cancer deaths 6
Incidence 
of cancer 
outcome in 
comparator 
group
19.5%  
(no 
timescale 
given)
5.8%  
(no timescale 
given)
Unclear N/A 11.1%  
(males 14.5%, 
females 10.8%)
5.2% (no 
timescale 
given)
10 year 
cumulative 
incidence (SD)
Any: 13.1 (2.0)
Solid: 11.4 (1.8)
Haematologic: 
1.1 (0.6)
Expected 
number of 
cancer deaths 5
Relative rate 
of cancer/
paraneoplastic 
outcomes in 
PMR versus 
comparator 
group
0-6 
months: 
1.69 
(1.18, 2.42)
6-12 
months: 
1.03  
(0.70, 1.51)
1-2 years: 
1.04  
(0.77, 1.40)
2-5 years: 
1.04  
(0.86, 1.26)
5-10 years: 
1.11  
(0.95, 1.30)
10+ years: 
1.00  
(0.82, 1.23)
OR 5.1  
(95%  
CI 2.9, 8.9)
“Risk of 
developing 
cancer not 
significantly 
different for the 
patients with 
PMR and TA 
compared to 
controls”
Overall SIR 
1.19  
(1.15, 1.23)
In first year 
2.26  
(2.10, 2.42)
After first 
year 1.03 
(1.03, 1.10)
RR 0.86  
(0.59, 1.26)
RR of death 
from cancer 
0.59  
(0.3, 1.17)
p=0.89 Described as 
non-significant
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patients with PMR and GCA (13). These 
authors included four (15, 17-19) of the 
eight studies described above. The stud-
ies of Bellan et al. (16) and Pfeiffer et al. 
(21) were published in the interim period, 
whilst the studies of Schauffelberger et al. 
(22) and Myklebust et al. (20) were not in-
cluded, (possibly because of a poorly de-
fined unexposed group and outcome was 
being death from cancer, rather than a can-
cer diagnosis respectively).
Ungprasert et al. (13) found a pooled in-
creased cancer risk of 14% (risk ratio 
1.14; 95% CI 1.05, 1.22). In the first 6 to 
12 months after PMR/GCA diagnosis, 
they calculated this increase in risk to be 
116% (2.16; 1.85, 2.53). However, after re-
moving the study that included only those 
hospitalised with PMR/GCA (18), these 
risk ratios were reduced. This resulted in a 
significantly increased risk in only the first 
6 months to a year after initial PMR diag-
nosis [overall 1.08 (0.99, 1.17); 0 to 6-12 
months post-diagnosis 1.76 (1.25, 2.46)].
Which cancers show an association  
with PMR?
Even the largest studies identified did not 
have sufficient power to confidently evalu-
ate which cancers were most common in 
Table III - Types and sites of cancer associated with PMR.
Muller et al. (15)
Rate per person year (95% CI)
Ji et al. (18)
SIR (95% CI)
Pfeiffer et al. (21)
Cumulative incidence at 10 years (SE)
In first 6 months
Lymphoma
PMR (n=1): 3.32 (0.47, 24.0)
Non-PMR (n=1): 0.09 (0.01, 0.64)
All blood
PMR (n=3): 0.70 (0.23, 2.18)
Non-PMR (n=3): 0.35 (0.11, 1.07)
Urinary tract
PMR (n=3): 0.36 (0.12, 1.12)
Non-PMR (n=4): 0.17 (0.07, 0.46)
Female reproductive
PMR (n=3): 0.75 (0.24, 2.34)
Non-PMR (n=7): 0.31 (0.15, 0.64)
Prostate
PMR (n=5): 0.26 (0.11, 0.63)
Non-PMR (n=4): 0.07 (0.03, 0.19)
Overall
Non-Hodgkins Lymphoma 1.32 (1.14, 1.52)
Leukaemia 2.16 (1.80, 2.58)
Acute myeloid leukaemia 2.69 (2.01, 3.52)
Melanoma 1.23 (1.02, 1.48)
Squamous cell 1.50 (1.33, 1.69)
Stomach 1.27 (1.07, 1.50)
Kidney 1.56 (1.30, 1.85)
Endometrium 0.81 (0.66, 0.98)
Nervous system 1.27 (1.02, 1.56)
Prostate 1.38 (1.27, 1.49)
Endocrine glands 1.51 (1.20, 1.88)
Myeloma 1.48 (1.17, 1.86)
In first year
Leukaemia 5.20 (3.53, 7.39)
Acute myeloid leukaemia 7.20 (4.02, 11.90)
Squamous cell 1.92 (1.36, 2.63)
Connective tissue 4.92 (2.34, 9.08)
Colon 1.56 (1.16, 2.06)
Stomach 2.21 (1.47, 3.20)
Liver 2.57 (1.72, 3.69)
Pancreas 1.76 (1.04, 2.79)
Kidney 5.07 (3.71, 6.77)
Bladder 2.39 (1.71, 3.25)
Ovary 2.34 (1.42, 3.61)
Lung 2.79 (2.16, 3.54)
Prostate 3.33 (2.84, 3.87)
Endocrine glands 4.05 (2.53, 6.14)
Myeloma 4.42 (2.83, 6.58)
After first year
Non-Hodgkins Lymphoma 3.46 (2.58, 4.54)
Leukaemia 1.81 (1.45, 2.22)
Acute myeloid leukaemia 2.15 (1.52, 2.96)
Melanoma 11.25 (1.02, 1.51)
Squamous cell 1.92 (1.36, 2.63)
Prostate 1.15 (1.05, 1.25)
Solid
PMR 13.1 (1.9)
Non-PMR 11.4 (1.8)
Haematologic
PMR 1.2 (0.6)
Non-PMR 1.1 (0.6)
SIR, standardised incidence ratio; CI, confidence interval.
No
n-
co
mm
er
cia
l u
se
 on
ly
REVIEW
30 Reumatismo 1/2018
S. Muller, S. Hider, T. Helliwell, et al.
the early stages after a diagnosis of PMR. 
However, limited evidence suggests that 
haematological and prostate cancers and 
lymphoma may be the most commonly di-
agnosed in those with incident PMR (15, 
16, 18) (Table III). 
What evidence is there to identify those 
with potential paraneoplastic PMR?
There was little evidence provided by the 
included studies as to the presentation of 
PMR patients subsequently diagnosed with 
cancer. However, Bellan et al. (16) reported 
that the odds of cancer were significantly 
higher in those aged over 75 years (OR 
2.56; 95% CI 1.0, 6.58), males (2.80; 1.10, 
7.20) and those with more than 6 tender 
joints (5.85; 1.65, 20.69).
Author’s conclusions as to the nature  
of the PMR-cancer relationship
The authors of the studies varied in their in-
terpretation of the associations they found 
between PMR and cancer. Haga et al. (17) 
and Myklebust et al. (19) considered the 
average length of time from PMR diagnosis 
to cancer diagnosis to be too long (greater 
than three years in both studies), to repre-
sent a paraneoplastic phenomenon. Bellan 
et al. (16) reported that in the 17 patients 
successfully treated for cancer, 8 experi-
enced a resolution in their PMR symptoms, 
which may indicate a paraneoplastic effect 
of PMR. Muller et al. (15) did not consider 
paraneoplastic syndrome, but suggested 
that cancer may initially be misdiagnosed 
as PMR, whilst Myklebust et al. (19) raised 
the possibility of surveillance bias giving 
rise to a PMR-cancer association. Howev-
er, they described the association as likely 
being coincidental.
n	 DISCUSSION
Statement of principal findings
There have been numerous reports in the 
literature of the co-occurrence of PMR 
with various malignant diseases. These 
have highlighted the potential paraneoplas-
tic nature of PMR (23), the chance occur-
rence of both conditions and the potential 
for PMR to have a transformative neo-
plastic effect (24) via an altered immune 
response (as seen in conditions such as 
primary Sjögren’s syndrome or rheumatoid 
arthritis), dependent on the time scales in-
volved. Furthermore the condition RS3PE 
(remitting seronegative symmetrical sy-
novitis with pitting oedema), which has 
clinical features which overlap with both 
seronegative rheumatoid arthritis and PMR 
is considered to be a paraneoplastic rheu-
matic disease caused by over-production of 
VEGF (7). 
Our review found some evidence of a 
short-term association between PMR and 
cancer (less than 6 to 12 months after PMR 
diagnosis). Whilst this raises the possibil-
ity of PMR as a paraneoplastic syndrome, 
definitive evidence is still lacking, given 
that PMR remains a clinical diagnosis and 
there is little evidence in the literature that 
PMR symptoms resolve following cancer 
treatment. Also, notwithstanding any other 
diagnoses, the symptoms of PMR may still 
rapidly improve with low dose glucocorti-
coids. In patients with RS3PE (which may 
resemble PMR), the response to glucocor-
ticoids in those with paraneoplastic disease 
is thought to be poor (25). In the medium to 
long term, the evidence regarding an asso-
ciation between PMR and cancer is mixed. 
The observed association between PMR 
symptoms and malignancy may represent 
misdiagnosis of a malignancy as PMR, or 
coexistence of two conditions in the same 
individual, either coincidentally, or as re-
sult of an underlying susceptibility (e.g., 
dysregulated immune system). 
Furthermore there may be some surveil-
lance bias, given that current guidelines 
suggest that malignancy should be ex-
cluded before the diagnosis of PMR can 
be made (2). This is particularly likely in 
those studies, where data are taken from 
routinely collected clinical or registry data, 
as it is not clear what investigations might 
or might not have been carried out on the 
unexposed group. This type of data pro-
vides the basis for the vast majority of the 
studies included in our review. However, 
the strongest association between PMR and 
cancer was seen in the study of Bellan et al. 
(16) where the unexposed group consisted 
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of people attending a secondary care clinic 
with a diagnosis of osteoarthritis. Hence, 
they are likely to also have undergone ad-
ditional tests, although not necessarily the 
same ones as those diagnosed with PMR.
In the papers included in this review, we 
were unable to find any convincing evi-
dence of clinical presentations that might 
be suggestive of cancer. Bellan et al. (16) 
provided some data on this issue, but the 
data were not clearly presented and their 
conclusions are contradicted by other stud-
ies in the wider literature (1, 26). There is 
considerable disagreement between studies 
as to what presenting features may suggest 
that further investigation is warranted.
Strengths and weaknesses of the 
study and in relation to other studies, 
discussing particularly any differences in 
results
Whilst we took a systematic approach to 
identifying the literature relevant to the 
question of whether PMR is associated with 
cancer, our review still has a number of limi-
tations. Primarily, it was difficult to decide 
how to specify our inclusion and exclusion 
criteria and to apply them in practice - spe-
cifically with regard to what to consider 
a research study and what to consider a 
case-series. We overcame this difficulty by 
adopting the approach of Ungprasert et al. 
(13), and including only those papers with a 
comparator group without PMR in our for-
mal review. However, in forming our con-
clusions, we have considered the wider lit-
erature, which included a number of sizable 
case series and case reports.
Also of note is that of the three studies find-
ing a significant association between PMR 
and cancer, two were the largest in the re-
view by some way (15, 18). Whilst the ad-
ditional power provided by a larger study 
does not necessarily make this finding 
surprising, the post hoc power calculation 
provided by Muller et al. (15) suggests that 
this study has sufficient power to detect a 
relatively small hazard ratio of 1.2. How-
ever, even these large studies were not able 
to confidently suggest the types or sites of 
cancer likely to be associated with PMR-
like symptoms.
Our systematic review excluded a large 
number of case reports and a number 
of case-series and case-control studies. 
Whilst it is difficult to make sense of the 
case report literature in a systematic way, 
there are some cancers that are frequently 
encountered in relation to PMR in this lit-
erature; leukaemias (24, 27-30), myelomas 
(30-36), lymphomas (30, 37-40) and lung 
cancer (41-45). Whilst we know that there 
is likely to be substantial publication bias 
in relation to case reports, it is not known 
what impact this might have. For example, 
it may be that more cases are noted and 
published when they involved the immune-
related cancers known to be associated 
with other rheumatological conditions, 
such as rheumatoid arthritis and lympho-
ma, or it may be that these are less likely to 
be published in favour of cancers that have 
not previously been associated with rheu-
matological disorders. The types of cancer 
identified from the papers included in our 
systematic review are broadly similar to 
those that appear commonly in the litera-
ture.
A recent review and case series concluded 
that PMR is not a paraneoplastic phenom-
enon and that the important thing was to 
conduct a rigorous diagnostic work-up be-
fore making the PMR diagnosis (1). This 
conclusion was based on a comparison of 
their clinical case series to studies in large 
databases, including those included in this 
review, specifically those by Ji et al. (18) 
and Muller et al. (15). Whilst we agree that 
there is a clear need to fully assess a patient 
before making a diagnosis of PMR and 
that this should likely include screening for 
common cancers, it is worth noting that the 
comparison of cancer diagnosis rates made 
in this paper is flawed, as it compares ab-
solute to relative rates, and that the rates of 
cancer diagnoses are not as high in other 
cohorts as the authors suggest.
Meaning of the study: possible 
mechanisms and implications for 
clinicians or policymakers
This study suggests that there is evidence of 
a short-term (<12 months) association be-
tween PMR and an underlying malignancy, 
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although there is insufficient evidence to 
label this as truly paraneoplastic. Given the 
non-specific nature of common PMR symp-
toms, such as shoulder and hip girdle pain 
and stiffness, fatigue and weight loss, which 
may also occur in patients with malignancy, 
establishing a definitive paraneoplastic di-
agnosis may be challenging. Some of these 
symptoms may be mediated by cytokine 
release such as IL-6 and VEGF, which may 
occur in both conditions (6, 7).
These findings support the guideline sug-
gestions regarding excluding cancer, sug-
gesting that relative simple, economic 
tests such as a chest X-ray in a smoker, or 
a prostate specific antigen (PSA) may be 
warranted as part of the diagnostic work up 
of PMR. However, the relative lack of as-
sociation of specific cancers suggests that 
more complex and costly investigations 
are not indicated for all patients. Clinicians 
however should be mindful of this PMR-
cancer association and consider additional 
investigations for a potential malignancy. 
However, we were unable to find convinc-
ing evidence as to which patients may be at 
highest risk of having a malignancy under-
lying their PMR symptoms.
Unanswered questions and future 
research
Despite a number of large studies and a sys-
tematic review and meta-analysis, there is 
not the evidence to suggest that PMR fulfils 
strict criteria as a paraneoplastic syndrome, 
particularly given the lack of evidence of 
improvement with treatment of the malig-
nancy. However, although not truly paraneo-
plastic, there does appear to be a short-term 
association between PMR-like symptoms 
and malignancy. It would therefore seem 
prudent for future work to concentrate on 
identifying those patients presenting with 
PMR-like symptoms who are most likely to 
experience a cancer diagnosis in the short-
term and to attempt to elucidate the cancers 
most likely to be associated with a PMR-
like presentation. This would better enable 
clinicians to target specific cancer screening 
in a clinical and cost effective manner to 
those most likely to benefit, during diagnos-
tic work up.
n	 CONCLUSIONS
In reality, except for intellectual curiosity, 
it is probably immaterial whether PMR 
represents a true paraneoplastic syndrome, 
or if it is just that the early symptoms of 
some cancers are difficult to distinguish 
from true PMR. What matters is that the 
correct diagnosis is made early, so that ap-
propriate treatment can be initiated. With 
this in mind, we suggest that when PMR 
is the suspected, or even obvious diagno-
sis, extra care is taken to assess whether 
the symptoms could be caused by an as 
yet unrecognised malignancy. Whilst there 
is limited evidence of specific malignan-
cies that may be most prone to present in a 
similar way to PMR, we suggest consider-
ation of prostate, haematological and lung 
cancers and lymphomas. Given the risk of 
cancer up to 12 months post PMR diagno-
sis, clinicians should maintain a high index 
of suspicion in PMR patients, especially in 
those who fail to respond to treatment or 
whose clinical appearance changes in some 
other way.
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